Abametapir

Summary

Abametapir (CHEMBL2205807) is an approved small molecule (ATC P03AX07); indicated across 2 conditions including lice infestation and parasitic infectious disease.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: P03AX07
• Indications: 2 conditions
• Clinical trials: 1
• Chemistry: 184.24 Da · C12H12N2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2205807
Name	Abametapir
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	15664
ATC	P03AX07
Molecular formula	C12H12N2
Molecular weight	184.24
InChIKey	PTRATZCAGVBFIQ-UHFFFAOYSA-N

SMILES: CC1=CN=C(C=C1)C2=NC=C(C=C2)C

IUPAC name: 5-methyl-2-(5-methyl-2-pyridinyl)pyridine

Also known as: Abametapir, HA-44, Ha44, Xeglyze, ABAMETAPIR, abametapir

Patent coverage: 339 distinct patent families (748 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 676 (90%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 4 (assay-derived). Sample: Protein deacetylase HDAC6, C-C chemokine receptor type 1, C-C chemokine receptor type 5, C-C chemokine receptor type 8.

Bioactivity

ChEMBL activities: 5 potent at pChembl ≥ 5 of 7 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
HDAC6	5.99	IC50	1022	nM	CHEMBL_ACT_23141048
CCR5	5.64	EC50	2300	nM	CHEMBL_ACT_12179668
CCR5	5.6	EC50	2512	nM	CHEMBL_ACT_12179410
CCR8	5.12	EC50	7500	nM	CHEMBL_ACT_12179458
CCR8	5.1	EC50	7943	nM	CHEMBL_ACT_12178146

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (2 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
lice infestation	4	MONDO:0003472	MONDO:0003472
parasitic infectious disease	4	MONDO:0005135	EFO:0001067

Clinical trials

Total trials: 1.

Phase distribution

Phase	Trials
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01518699	PHASE1	COMPLETED	Study to Evaluate the Effect of Ha44 Gel on the Electrocardiogram in Healthy Volunteers

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).